CYP19A1 and breast carcinoma: To advance this idea, it would be valuable to examine whether the observations in the laboratory with the evolution of tamoxifen drug resistance apply to other SERMs and to breast cancer cells that have adapted to oestrogen deprivation, that is, as an expression of resistance to aromatase inhibitors.